MaxCyte (NASDAQ:MXCT) Stock Rating Reaffirmed by Stephens

MaxCyte (NASDAQ:MXCT)‘s stock had its “overweight” rating reissued by equities research analysts at Stephens in a report issued on Tuesday, Benzinga reports. They presently have a $11.00 price target on the stock. Stephens’ price target would suggest a potential upside of 194.12% from the stock’s current price.

MXCT has been the topic of several other research reports. BTIG Research cut their price target on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th.

MaxCyte Trading Down 1.6 %

Shares of NASDAQ MXCT opened at $3.74 on Tuesday. The company has a market capitalization of $390.46 million, a price-to-earnings ratio of -10.11 and a beta of 1.34. MaxCyte has a twelve month low of $2.45 and a twelve month high of $5.55. The business has a 50 day simple moving average of $4.25 and a 200-day simple moving average of $4.32.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. The company had revenue of $15.67 million for the quarter, compared to analysts’ expectations of $15.60 million. As a group, equities analysts predict that MaxCyte will post -0.53 earnings per share for the current year.

Insider Transactions at MaxCyte

In related news, Director John Joseph Johnston sold 5,000 shares of the company’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $5.12, for a total value of $25,600.00. Following the completion of the sale, the director now owns 120,583 shares of the company’s stock, valued at $617,384.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On MaxCyte

Hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. bought a new position in MaxCyte during the fourth quarter valued at about $29,000. Victory Capital Management Inc. bought a new stake in shares of MaxCyte in the 3rd quarter worth approximately $31,000. Johnson Investment Counsel Inc. acquired a new stake in MaxCyte during the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC lifted its stake in MaxCyte by 47,100.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock valued at $55,000 after purchasing an additional 11,775 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in MaxCyte by 350.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $56,000 after buying an additional 9,323 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.